Results 101 to 110 of about 1,087,915 (317)
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert ...
최치환, 최기홍, 성진실
core +1 more source
Design and analysis strategies for robust microbiome ageing research
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik +5 more
wiley +1 more source
Weihong Ma,1,2,* Yinyin Li,1,* Yinying Lu,1,2 Zhipeng Liang,3 Hongli Yu,1,2 Jie Han,1,2 Jiaqi Liu,1,2 Wenjing Wang,1,2 Caiyun Peng,1 Jiamin Cheng1 1Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital ...
Ma W +9 more
doaj
Improvements in imaging technology allow exploitation of the dual blood supply of the liver to aid in the identification and characterisation of both malignant and benign liver lesions. Imaging techniques available include contrast enhanced ultrasound, computed tomography and magnetic resonance imaging.
Ben, Ariff +8 more
openaire +2 more sources
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
Background Drug resistance is one of the major concerns in the treatment of hepatocellular carcinoma (HCC). The aim of the present study was to determine whether aberrant high expression of the inhibitor of differentiation 1(ID1) confers oxaliplatin ...
Xin Yin +9 more
doaj +1 more source
Introduction The controversy over the intake of antioxidants supplements in cancer patients persists for decades without efficient guideline. In tumor cells, increased metabolic activities are accompanied with increased antioxidants production to adapt ...
Sze, MF +9 more
core
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Fan Yao,1,2,* Jianliang Miao,3,* Bing Quan,1,2 Jinghuan Li,1,2 Bei Tang,1,2 Shenxin Lu,1,2 Xin Yin1,2 1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2National Clinical Research Center ...
Yao F +6 more
doaj
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source

